Insights - Yesterday, Medicenna released additional data for their IL-2 program MDNA11. The 3rd cohort (n=4) used a dose of 30 µg/kg (IL-2 content of 6 µg/kg). Remember, MDNA11 is … Continue Reading
PremiumInsights - Genocea (GNCA) reported underwhelming data at AACR for their targeted TIL approach, GEN-011. Remember, Genocea was using neoantigen reactive T-cells drawn from the peripheral blood … Continue Reading
PremiumInsights - Affimed & MD Anderson reported an update on their AFM13+NK cell program. The data was very promising and exceeded expectations with continued dose response and durability. The Data … Continue Reading
PremiumInsights - Big news this week in bio land is that Nektar/Bristol Myers IL-2 drug failed to benefit patients with melanoma. The primary endpoints of overall survival (OS) and … Continue Reading
PremiumInsights - Yesterday, Medicenna (MDNA) announced a clinical advisory board and strategic advisors. In the end of the press release, MDNA disclosed that Chief Scientific Officer Dr. Kevin Moulder … Continue Reading
PremiumInsights - 9 Meters Bio (NMTR) shared yesterday that their topline results for Phase 2 in Short Bowel Syndrome (SBS) will be pushed back to Q2 2022. … Continue Reading
PremiumInsights - The XBI biotech index was starting a see some consolidation during February in the low-mid $90s. However, that was interrupted by the ongoing tensions between … Continue Reading
Premium
